Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease

Journal of Leukocyte Biology

Volumn 82, Issue 5, 2007, Pages 1083-1094

  Reynolds, Ashley D ^a,b   Banerjee, Rebecca ^a,b   Liu, Jianou ^a,b   Gendelman, Howard E ^a,b   Mosley, R Lee ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Inflammation; Microglia; Neurodegeneration; Neuroprotection

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; CD3 ANTIGEN; NEUROTROPHIC FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; EFFECTOR CELL; GLIA CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IN VIVO STUDY; INFLAMMATION; MALE; MICROGLIA; MOUSE; NEUROPROTECTION; NEWBORN; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; UPREGULATION;

ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; MPTP POISONING; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; MUS;

EID: 36249032567     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0507296     Document Type: Article

References (89)

1. Fahn, S., Przedborski, S. (2000) Merritt's Neurology. New York, NY, USA, Lippincott, Williams & Wilkins.
2. Dauer, W., Przedborski, S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909.
3. Savitt, J. M., Dawson, V. L., Dawson, T. M. (2006) Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116, 1744-1754.
4. Lorincz, M. T. (2006) Clinical implications of Parkinson's disease genetics. Semin. Neurol. 26, 492-498.
5. Liu, B. (2006) Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J. 8, E606-E621.
6. Dhib-Jalbut, S., Arnold, D. L., Cleveland, D. W., Fisher, M., Friedlander, R. M., Mouradian, M. M., Przedborski, S., Trapp, B. D., Wyss-Coray, T., Yong, V. W. (2006) Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J. Neuroimmunol. 176, 198-215.
7. Chade, A. R., Kasten, M., Tanner, C. M. (2006) Nongenetic causes of Parkinson's disease. J. Neural Transm. Suppl. 2006, 147-151.
8. Cassarino, D. S., Fall, C. P., Swerdlow, R. H., Smith, T. S., Halvorsen, E. M., Miller, S. W., Parks, J. P., Parker Jr., W. D., Bennett Jr., J. P. (1997) Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta 1362, 77-86.
9. Suzuki, K., Mizuno, Y., Yoshida, M. (1990) Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-like compounds on mitochondrial respiration. Adv. Neurol. 53, 215-218.
10. Yoshimoto, Y., Lin, Q., Collier, T. J., Frim, D. M., Breakefield, X. O., Bohn, M. C. (1995) Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Res. 691, 25-36.
11. Czlonkowska, A., Kohutnicka, M., Kurkowska-Jastrzebska, I., Czlonkowski, A. (1996) Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5, 137-143.
12. McGeer, P. L., Itagaki, S., Boyes, B. E., McGeer, E. G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291.
13. Mehlhorn, G., Hollborn, M., Schliebs, R. (2000) Induction of cytokines in glial cells surrounding cortical β-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int. J. Dev. Neurosci. 18, 423-431.
14. Rogove, A. D., Tsirka, S. E. (1998) Neurotoxic responses by microglia elicited by excitotoxic injury in the mouse hippocampus. Curr. Biol. 8, 19-25.
15. Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D. K., Ischiropoulos, H., Przedborski, S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763-1771.
16. Thomas, M. P., Kathryn, C., Reynolds, A., Vitvitsky, V., Banerjee, R., Gendelman, H. E. (2007) Ion channel blockade attenuates aggregated α synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. J. Neurochem. 100, 503-519.
17. Benner, E. J., Mosley, R. L., Destache, C. J., Lewis, T. B., Jackson-Lewis, V., Gorantla, S., Nemachek, C., Green, S. R., Przedborski, S., Gendelman, H. E. (2004) Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 101, 9435-9440.
18. Laurie, C., Reynolds, A., Cuskun, O., Bowman, E., Gendelman, H. E., Mosley, R. L. (2007) CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neuroimmunol. 183, 60-68.
19. Przedborski, S., Jackson-Lewis, V., Naini, A. B., Jakowec, M., Petzinger, G., Miller, R., Akram, M. (2001) The Parkinsonian toxin 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76, 1265-1274.
20. Tieu, K., Perier, C., Caspersen, C., Teismann, P., Wu, D. C., Yan, S. D., Naini, A., Vila, M., Jackson-Lewis, V., Ramasamy, R., Przedborski, S. (2003) D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J. Clin. Invest. 112, 892-901.
21. Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., Przedborski, S. (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5, 1403-1409.
22. Dobrenis, K. (1998) Microglia in cell culture and in transplantation therapy for central nervous system disease. Methods 16, 320-344.
23. Yagi, H., Nomura, T., Nakamura, K., Yamazaki, S., Kitawaki, T., Hori, S., Maeda, M., Onodera, M., Uchiyama, T., Fujii, S., Sakaguchi, S. (2004) Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int. Immunol. 16, 1643-1656.
24. Markey, S. P., Johannessen, J. N., Chiueh, C. C., Burns, R. S., Herkenham, M. A. (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism. Nature 311, 464-467.
25. Giovanni, A., Sieber, B. A., Heikkila, R. E., Sonsalla, P. K. (1994) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: systemic administration. J. Pharmacol. Exp. Ther. 270, 1000-1007.
26. Ortiz, G. G., Zuniga-Gonzalez, G., Garcia, J. J., Torres-Bugarin, O., Zamora-Perez, A., Bitzer-Quintero, O. K. (2003) 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced lipid peroxidation and DNA damage in mouse bone marrow and blood. Environ. Mol. Mutagen. 41, 64-68.
27. Przedborski, S., Tieu, K., Perier, C., Vila, M. (2004) MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J. Bioenerg. Biomembr. 36, 375-379.
28. Jackson-Lewis, V., Jakowec, M., Burke, R. E., Przedborski, S. (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4, 257-269.
29. Reynolds, A., Laurie, C., Mosley, R. L., Gendelman, H. E. (2007) Oxidative stress and the pathogenesis of neurodegenerative disorders. Int. Rev. Neurobiol. 82, 297-325.
30. Boska, M. D., Lewis, T. B., Destache, C. J., Benner, E. J., Nelson, J. A., Uberti, M., Mosley, R. L., Gendelman, H. E. (2005) Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease. J. Neurosci. 25, 1691-1700.
31. Aharoni, R., Teitelbaum, D., Leitner, O., Meshorer, A., Sela, M., Arnon, R. (2000) Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc. Natl. Acad. Sci. USA 97, 11472-11477.
32. Hong, J., Li, N., Zhang, X., Zheng, B., Zhang, J. Z. (2005) Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc. Natl. Acad. Sci. USA 102, 6449-6454.
33. Kipnis, J., Avidan, H., Caspi, R. R., Schwartz, M. (2004) Dual effect of CD4+CD25+ regulatory T cells in neurodegeneration: a dialogue with microglia. Proc. Natl. Acad. Sci. USA 101 (Suppl. 2), 14663-14669.
34. He, Y., Appel, S., Le, W. (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909, 187-193.
35. Sriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I., O'Callaghan, J. P. (2006) Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-α. FASEB J. 20, 670-682.
36. Smeyne, R. J., Jackson-Lewis, V. (2005) The MPTP model of Parkinson's disease. Brain Res. Mol. Brain Res. 134, 57-66.
37. Abraham, H., Lazar, G. (2000) Early microglial reaction following mild forebrain ischemia induced by common carotid artery occlusion in rats. Brain Res. 862, 63-73.
38. Garcao, P., Oliveira, C. R., Agostinho, P. (2006) Comparative study of microglia activation induced by amyloid-β and prion peptides: role in neurodegeneration. J. Neurosci. Res. 84, 182-193.
39. Hirayama, A., Okoshi, Y., Hachiya, Y., Ozawa, Y., Ito, M., Kida, Y., Imai, Y., Kohsaka, S., Takashima, S. (2001) Early immunohistochemical detection of axonal damage and glial activation in extremely immature brains with periventricular leukomalacia. Clin. Neuropathol. 20, 87-91.
40. Lynch, W. P., Robertson, S. J., Portis, J. L. (1995) Induction of focal spongiform neurodegeneration in developmentally resistant mice by implantation of murine retrovirus-infected microglia. J. Virol. 69, 1408-1419.
41. McGeer, P. L., Yasojima, K., McGeer, E. G. (2001) Inflammation in Parkinson's disease. Adv. Neurol. 86, 83-89.
42. Orr, C. F., Rowe, D. B., Mizuno, Y., Mori, H., Halliday, G. M. (2005) A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 128, 2665-2674.
43. Yamada, T., McGeer, P. L., McGeer, E. G. (1992) Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol. (Berl.) 84, 100-104.
44. Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J. S., Zhang, J. (2005) Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19, 533-542.
45. Choi, D. K., Pennathur, S., Perier, C., Tieu, K., Teismann, P., Wu, D. C., Jackson-Lewis, V., Vila, M., Vonsattel, J. P., Heinecke, J. W., Przedborski, S. (2005) Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J. Neurosci. 25, 6594-6600.
46. Kurkowska-Jastrzebska, I., Litwin, T., Joniec, I., Ciesielska, A., Przybylkowski, A., Czlonkowski, A., Czlonkowska, A. (2004) Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int. Immunopharmacol. 4, 1307-1318.
47. Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L., Luecke, S., Phebus, L. A., Bymaster, F. P., Paul, S. M. (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 98, 14669-14674.
48. Vijitruth, R., Liu, M., Choi, D. Y., Nguyen, X. V., Hunter, R. L., Bing, G. (2006) Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J. Neuroinflammation 3, 6.
49. Teismann, P., Tieu, K., Choi, D. K., Wu, D. C., Naini, A., Hunot, S., Vila, M., Jackson-Lewis, V., Przedborski, S. (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. USA 100, 5473-5478.
50. Teismann, P., Ferger, B. (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39, 167-174.
51. Chen, H., Jacobs, E., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., Ascherio, A. (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol. 58, 963-967.
52. Chen, H., Zhang, S. M., Hernan, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., Ascherio, A. (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60, 1059-1064.
53. Hoffmann, P., Ermann, J., Edinger, M., Fathman, C. G., Strober, S. (2002) Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196, 389-399.
54. Morgan, M. E., Flierman, R., van Duivenvoorde, L. M., Witteveen, H. J., van Ewijk, W., van Laar, J. M., de Vries, R. R., Toes, R. E. (2005) Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum. 52, 2212-2221.
55. Goudy, K. S., Burkhardt, B. R., Wasserfall, C., Song, S., Campbell-Thompson, M. L., Brusko, T., Powers, M. A., Clare-Salzler, M. J., Sobel, E. S., Ellis, T. M., Flotte, T. R., Atkinson, M. A. (2003) Systemic overexpression of IL-10 induces CD4+CD25+ cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. J. Immunol. 171, 2270-2278.
56. Liu, H., Hu, B., Xu, D., Liew, F. Y. (2003) CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-β, and CTLA4. J. Immunol. 171, 5012-5017.
57. Xu, D., Liu, H., Komai-Koma, M., Campbell, C., McSharry, C., Alexander, J., Liew, F. Y. (2003) CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J. Immunol. 170, 394-399.
58. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., Toda, M. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164.
59. Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C. H., Hanke, T., Hunig, T., Kerkau, T., Gold, R. (2005) Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J. Exp. Med. 202, 445-455.
60. Kohm, A. P., Carpentier, P. A., Anger, H. A., Miller, S. D. (2002) Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169, 4712-4716.
61. Tischner, D., Weishaupt, A., van den Brandt, J., Muller, N., Beyersdorf, N., Ip, C. W., Toyka, K. V., Hunig, T., Gold, R., Kerkau, T., Reichardt, H. M. (2006) Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain 129, 2635-2647.
62. Wang, Z., Hong, J., Sun, W., Xu, G., Li, N., Chen, X., Liu, A., Xu, L., Sun, B., Zhang, J. Z. (2006) Role of IFN-γ in induction of Foxp3 and conversion of CD4 CD25 T cells to CD4 Tregs. J. Clin. Invest. 116, 2434-2441.
63. Frenkel, D., Huang, Z., Maron, R., Koldzic, D. N., Moskowitz, M. A., Weiner, H. L. (2005) Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J. Neurol. Sci. 233, 125-132.
64. Hauben, E., Agranov, E., Gothilf, A., Nevo, U., Cohen, A., Smirnov, I., Steinman, L., Schwartz, M. (2001) Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J. Clin. Invest. 108, 591-599.
65. Hauben, E., Butovsky, O., Nevo, U., Yoles, E., Moalem, G., Agranov, E., Mor, F., Leibowitz-Amit, R., Pevsner, E., Akselrod, S., Neeman, M., Cohen, I. R., Schwartz, M. (2000) Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J. Neurosci. 20, 6421-6430.
66. Jones, T. B., Ankeny, D. P., Guan, Z., McGaughy, V., Fisher, L. C., Basso, D. M., Popovich, P. G. (2004) Passive or active immunization with myelin basic protein impairs neurological function and exacerbates neuropathology after spinal cord injury in rats. J. Neurosci. 24, 3752-3761.
67. Jones, T. B., Basso, D. M., Sodhi, A., Pan, J. Z., Hart, R. P., MacCallum, R. C., Lee, S., Whitacre, C. C., Popovich, P. G. (2002) Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: implications for autoimmune vaccine therapy. J. Neurosci. 22, 2690-2700.
68. Kipnis, J., Mizrahi, T., Yoles, E., Ben-Nun, A., Schwartz, M. (2002) Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity. J. Neuroimmunol. 130, 78-85.
69. Kipnis, J., Yoles, E., Porat, Z., Cohen, A., Mor, F., Sela, M., Cohen, I. R., Schwartz, M. (2000) T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc. Natl. Acad. Sci. USA 97, 7446-7451.
70. Moalem, G., Leibowitz-Amit, R., Yoles, E., Mor, F., Cohen, I. R., Schwartz, M. (1999) Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5, 49-55.
71. Wolf, S. A., Fisher, J., Bechmann, I., Steiner, B., Kwidzinski, E., Nitsch, R. (2002) Neuroprotection by T-cells depends on their subtype and activation state. J. Neuroimmunol. 133, 72-80.
72. Baba, Y., Kuroiwa, A., Uitti, R. J., Wszolek, Z. K., Yamada, T. (2005) Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat. Disord. 11, 493-498.
73. Bas, J., Calopa, M., Mestre, M., Mollevi, D. G., Cutillas, B., Ambrosio, S., Buendia, E. (2001) Lymphocyte populations in Parkinson's disease and in rat models of Parkinsonism. J. Neuroimmunol. 113, 146-152.
74. Kullberg, M. C., Jankovic, D., Gorelick, P. L., Caspar, P., Letterio, J. J., Cheever, A. W., Sher, A. (2002) Bacteria-triggered CD4(+) T regulatory cells suppress Helicobacter hepaticus-induced colitis. J. Exp. Med. 196, 505-515.
75. Wang, Y. H., Ito, T., Wang, Y. H., Homey, B., Watanabe, N., Martin, R., Barnes, C. J., McIntyre, B. W., Gilliet, M., Kumar, R., Yao, Z., Liu, Y. J. (2006) Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity 24, 827-838.
76. Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M., Takahashi, T. (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182, 18-32.
77. Thornton, A. M., Shevach, E. M. (2000) Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 164, 183-190.
78. Cederbom, L., Hall, H., Ivars, F. (2000) CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur. J. Immunol. 30, 1538-1543.
79. Suri-Payer, E., Amar, A. Z., Thornton, A. M., Shevach, E. M. (1998) CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 160, 1212-1218.
80. Avidan, H., Kipnis, J., Butovsky, O., Caspi, R. R., Schwartz, M. (2004) Vaccination with autoantigen protects against aggregated β-amyloid and glutamate toxicity by controlling microglia: effect of CD4+CD25+ T cells. Eur. J. Immunol. 34, 3434-3445.
81. Nakamura, K., Kitani, A., Fuss, I., Pedersen, A., Harada, N., Nawata, H., Strober, W. (2004) TGF-β 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J. Immunol. 172, 834-842.
82. Nakamura, K., Kitani, A., Strober, W. (2001) Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 194, 629-644.
83. Pontoux, C., Banz, A., Papiernik, M. (2002) Natural CD4 CD25(+) regulatory T cells control the burst of superantigen-induced cytokine production: the role of IL-10. Int. Immunol. 14, 233-239.
84. Kryczek, I., Wei, S., Zou, L., Zhu, G., Mottram, P., Xu, H., Chen, L., Zou, W. (2006) Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J. Immunol. 177, 40-44.
85. Arimoto, T., Choi, D. Y., Lu, X., Liu, M., Nguyen, X. V., Zheng, N., Stewart, C. A., Kim, H. C., Bing, G. (2006) Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol. Aging, 28, 894-906.
86. Kim, W. K., Hwang, S. Y., Oh, E. S., Piao, H. Z., Kim, K. W., Han, I. O. (2004) TGF-β1 represses activation and resultant death of microglia via inhibition of phosphatidylinositol 3-kinase activity. J. Immunol. 172, 7015-7023.
87. Krieglstein, K., Suter-Crazzolara, C., Fischer, W. H., Unsicker, K. (1995) TGF-β superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity. EMBO J. 14, 736-742.
88. Butovsky, O., Ziv, Y., Schwartz, A., Landa, G., Talpalar, A. E., Pluchino, S., Martino, G., Schwartz, M. (2006) Microglia activated by IL-4 or IFN-γ differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol. Cell. Neurosci. 31, 149-160.
89. Kurkowska-Jastrzebska, I., Wronska, A., Kohutnicka, M., Czlonkowski, A., Czlonkowska, A. (1999) MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. Acta Neurobiol. Exp. (Wars) 59, 1-8.